Information Provided By: 
Fly News Breaks for May 9, 2016
MDVN
May 9, 2016 | 15:44 EDT
Needham analyst Chad Messer said Medivation reported the third consecutive disappointment of Xtandi and continues to believe the long-term expectations for the drug are overly optimistic. The analyst said Medivation has been increasing spending on its proprietary pipeline, in attempt to gain future growth. Given the uncertainty of success in clinical development and rising competitive threats, Messer views a buyout as an attractive option for investors but sees little upside to shares at current levels.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
